Primary and Secondary Immunodeficiencies
We recommend
Subcutaneous vs. Intravenous Immunoglobulins in Patients with CLL
Secondary antibody immunodeficiency is a common complication in patients with chronic lymphocytic leukemia (CLL), and infections, along with secondary malignancies, are the leading cause of death in these patients. Hypogammaglobulinemia can be managed with immunoglobulin replacement therapy (IGRT). Besides the classic intravenous form (IVIG), a subcutaneous form (SCIG) is also available. An Italian retrospective study published in the journal Current Oncology compared their efficacy in secondary immunodeficiency in CLL patients.
10 Warning Signs of Primary and Secondary Immunodeficiencies
The Jeffrey Modell Foundation (JMF) proposed 10 warning signs of primary immunodeficiencies (PID).…
Effectiveness and Safety of Initiating Treatment for Primary Immunodeficiency with Subcutaneously Administered Immunoglobulins – A Systematic Review of the Literature
The aim of the systematic review of the literature published last year was to evaluate the…
Articles on this topic
Facilitated Immunoglobulin Substitution Therapy in Paediatric Patients with Immunodeficiency – Real-World Data
Patients with humoral immunodeficiency are indicated for immunoglobulin substitution therapy.…
Subcutaneous Immunoglobulin Therapy in Patients with Secondary Immunodeficiency – Real-World Data
Even in patients with secondary immunodeficiency (SID), immunoglobulin substitution can be indicated....
Measurement of Serum Trough Levels of IgG as an Adequate and Beneficial Indicator for Assessing the Pharmacokinetics of Subcutaneously Administered Products
For many patients with primary immunodeficiency, lifelong immunoglobulin substitution is essential...
Subcutaneous Immunoglobulin Substitution in Ig-Naive Patients with PID – Available Efficacy and Safety Data
The prevalence of primary immunodeficiencies (PID) is estimated at 1:10,000. Below, we…
Long-term Efficacy, Safety, and Tolerability of Normal Human IgG with Facilitated Absorption in Patients with Humoral Immunodeficiency
The treatment of patients with humoral immunodeficiency is long-term and therefore needs to be…
fSCIG in Elderly Patients with PID or SID in Real Clinical Practice
The work of a team of German and Dutch authors presents data on the real clinical use of 10%…
ID 360 – Immunodeficiency in Interdisciplinary Collaboration 2022
For the second time, a two-day meeting titled "ID 360 – Immunodeficiency in Interdisciplinary…
Recommendations for Substitution Therapy with Immunoglobulins in Hemato-oncological Patients with Secondary Immunodeficiency – Expert Consensus According to the DELPHI Methodology
Substitution therapy with immunoglobulins is used not only for patients with primary immunodeficiencies....
PID in children manifest differently, 10 warning signs help in diagnosis
We asked MUDr. Eva Hlaváčková from the Department of Clinical Immunology and Allergology,…
Should patients with primary immunodeficiencies fear COVID-19 more than the general population?
The body fights the new SARS-CoV-2 virus, which causes COVID-19, in a similar way to other…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- PID in children manifest differently, 10 warning signs help in diagnosis
- Should patients with primary immunodeficiencies fear COVID-19 more than the general population?
- 10 Warning Signs of Primary and Secondary Immunodeficiencies
- Facilitated Immunoglobulin Substitution Therapy in Paediatric Patients with Immunodeficiency – Real-World Data
- Subcutaneous Immunoglobulin Therapy in Patients with Secondary Immunodeficiency – Real-World Data
- Measurement of Serum Trough Levels of IgG as an Adequate and Beneficial Indicator for Assessing the Pharmacokinetics of Subcutaneously Administered Products
Journal on this topic
Related topic
Interesting links